Insider filing
Traded May 29 · filed 3 days later
Compensation award — excluded from discretionary-purchase analysis.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Holdings as of Mar 31, 2026 (Q1 2026) · Filed May 7, 2026
78 tracked managers disclosed the same change for Q1 2026. From a 13F filed May 7, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
Reduced
Compared with the manager's Q4 2025 13F
524,826
444,413
−15.3%
Share count drives classification; reported value also moves with price
0.26%
Within the filing's reported positions, not the manager's total assets
78
For Q1 2026
Insider filing
Traded May 29 · filed 3 days later
Compensation award — excluded from discretionary-purchase analysis.
Federal contracts
4571812561!PROCARDIA xl 30 mg tablet 100S
The Department of Defense placed a delivery order with Pfizer for $25K worth of Procaria XL tablets. This is the second largest of 10 recent contracts for Pfizer under an existing agreement and was open to any bidder, making it a routine purchase.
Federal contracts
4571890796!CYKLOKAPRON 1,000 MG/10 ml vl 10ML
The Department of Defense placed a delivery order for $2.2K of Pfizer's CYKLOKAPRON on May 20, 2026. This is a routine purchase under an existing contract open to all bidders, part of $652K in similar awards over the past year.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.